Targeting of Inflammatory Pathways with R2CHOP in High-Risk DLBCL

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma, and front line therapies have not improved overall outcomes since the advent of immunochemotherapy. By pairing DNA and gene expression data with clinical response data, we identified a high-risk subset of non-GCB DLBCL patients chara...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartert, Keenan T., Wenzl, Kerstin, Krull, Jordan E., Manske, Michelle, Sarangi, Vivekananda, Asmann, Yan, Larson, Melissa C., Maurer, Matthew J., Slager, Susan, Macon, William R., King, Rebecca L., Feldman, Andrew L., Gandhi, Anita K., Link, Brian K., Habermann, Thomas M., Yang, Zhi-Zhang, Ansell, Stephen M., Cerhan, James R., Witzig, Thomas E., Nowakowski, Grzegorz S., Novak, Anne J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483252/
https://www.ncbi.nlm.nih.gov/pubmed/32139889
http://dx.doi.org/10.1038/s41375-020-0766-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483252/
https://www.ncbi.nlm.nih.gov/pubmed/32139889
http://dx.doi.org/10.1038/s41375-020-0766-4

Ejemplares similares